Evan David Seigerman
Stock Analyst at BMO Capital
(1.87)
# 2,896
Out of 4,829 analysts
38
Total ratings
33.33%
Success rate
-9.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $6.52 | +53.37% | 1 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $865 → $800 | $575.63 | +38.98% | 6 | Apr 30, 2025 | |
| NVO Novo Nordisk | Downgrades: Market Perform | $105 → $64 | $67.74 | -5.52% | 6 | Apr 17, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $80.43 | +19.36% | 4 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $208 → $215 | $190.07 | +13.12% | 7 | Feb 3, 2025 | |
| REPL Replimune Group | Maintains: Outperform | $18 → $27 | $7.86 | +243.51% | 3 | Jan 22, 2025 | |
| GPCR Structure Therapeutics | Maintains: Outperform | $83 → $100 | $24.62 | +306.17% | 2 | Jun 7, 2024 | |
| AMGN Amgen | Maintains: Outperform | $336 → $355 | $274.76 | +29.20% | 3 | May 3, 2024 | |
| PFE Pfizer | Reiterates: Outperform | $33 → $36 | $23.09 | +55.91% | 4 | May 2, 2024 | |
| CADL Candel Therapeutics | Maintains: Outperform | $9 → $3 | $5.01 | -40.12% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $755.57 | -47.59% | 1 | Sep 6, 2022 |
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $6.52
Upside: +53.37%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Outperform
Price Target: $865 → $800
Current: $575.63
Upside: +38.98%
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105 → $64
Current: $67.74
Upside: -5.52%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $80.43
Upside: +19.36%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208 → $215
Current: $190.07
Upside: +13.12%
Replimune Group
Jan 22, 2025
Maintains: Outperform
Price Target: $18 → $27
Current: $7.86
Upside: +243.51%
Structure Therapeutics
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $24.62
Upside: +306.17%
Amgen
May 3, 2024
Maintains: Outperform
Price Target: $336 → $355
Current: $274.76
Upside: +29.20%
Pfizer
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $23.09
Upside: +55.91%
Candel Therapeutics
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.01
Upside: -40.12%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $755.57
Upside: -47.59%